💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Sanofi, Merck begin vet drugs sell-off -sources

Published 10/21/2010, 01:29 PM
Updated 10/21/2010, 01:32 PM

* Antitrust issues spur sales from $5 bln world No. 1

* Month before bids due for whole package or parts -sources

* Products with $500 million annual sales said to be offered

By Quentin Webb

LONDON, Oct 21 (Reuters) - Merck & Co Inc and Sanofi-Aventis SA have begun selling parts of the businesses they are combining to form the world's largest animal-health operation, people familiar with the matter said.

The two drugmakers are selling some product lines to allay competition concerns, offering smaller players in the $19 billion animal-health industry a last clear chance to bulk up.

Bidders are being offered the chance to buy products with about $500 million in combined annual sales, the people said, either in a single bundle or in several smaller packages.

"We will be proactive on divestitures in markets identified by our antitrust advisors as likely to require such divestitures. We will propose solutions to regulators," a Merck spokeswoman said in an email.

She said the two were preparing to file notifications with antitrust regulators in Europe and the United States, but added: "It would be premature to speculate about any eventual outcome."

Sanofi did not immediately respond to requests for comment. (Reporting by Quentin Webb; additional reporting by Philipp Halstrick in Frankfurt, Ransdell Pierson in New York, and Jessica Hall in Philadelphia; Editing by Will Waterman)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.